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Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke worldwide and represents a signiﬁcant health
problem. The pathogenesis and natural history of ICAD are poorly understood, and rigorous treatment paradigms do not exist as
theydoforextracranialatherosclerosis.Currently,thebesttreatmentforICADremainsaspirintherapy,butmanypatientswhoare
placed on aspirin continue to experience recurrent strokes. As microsurgical and endovascular techniques continue to evolve, the
role of extracranial to intracranial bypass operations and stenting are increasingly being reconsidered. We performed a PubMed
review of the English literature with a particular focus on treatment options for ICAD and present evidence-based data for the role
of surgery and stenting in ICAD against medical therapy alone.
1.Introduction
Intracranial atherosclerotic disease (ICAD) is the process
by which atherosclerotic plaques aﬀect large intracranial ar-
teries. Intracranial stenosis represents the most advanced
stage of ICAD and is a precursor to ischemic stroke. ICAD is
the leading cause of stroke among patients of Asian ancestry
[1],andHispanicsandAfricansalsoappeartobemoreprone
to [2] intracranial as opposed to extracranial atherosclerosis.
Whites, on the other hand, are less aﬀected, but ICAD is still
thought to account for almost 10% of ischemic strokes in
this subpopulation [3]. Thus, worldwide, ICAD may be the
leading the cause of ischemic stroke.
Atherosclerotic lesions, as elsewhere in the body, develop
silently and insidiously over years prior to becoming sud-
denly symptomatic in the form of a stroke. Symptomatic
ICADisburdenedwithanunacceptablyhighrecurrencerate,
suchthatamongpatientswithsymptomaticICADand>70%
stenosis, approximately23% willhavearecurrent strokeover
the ensuing 12 months [4], and nearly half of these recurrent
strokes tend to be disabling. The prevalence and natural his-
tory of asymptomatic ICAD are much less understood, par-
ticularly in people of European descent.
Due to this lack of insight, rigorous treatment paradigms
do not exist for ICAD as they do for extracranial atheroscle-
rotic disease. The treatment strategies for ICAD include
optimal medical management, surgical, and endovascular
options.Inthispaper,weaimtodeﬁnetheoptimaltreatment
strategies for this devastating disease.
2. Methods
MEDLINE and PubMed searches of the English literature
were performed with the following keywords: intracranial
atherosclerosis, extracranial-intracranial bypass, intracranial
stenting, Wingspan, drug-eluding stent, stroke, and medical
therapy. The relevant literature was reviewed and was sup-
plemented as necessary from the bibliography of selected
articles, with a particular focus on articles which discussed
therapeutic interventions for ICAD.
3. Results
3.1. Optimal Medical Management. The results of the War-
farin-Aspirin Symptomatic Intracranial Disease (WASID)
study not only demonstrated the role for medical therapy in2 International Journal of Vascular Medicine
ICAD, but also provided important information regarding
the natural history. Patients presenting within 90 days
of a transient ischemic attack (TIA) or nonsevere stroke
attributable to angiographically proven high-grade (50–
99%) stenosis of a major intracranial artery were given
either aspirin or warfarin and were followed for the primary
endpoints of ischemic stroke, hemorrhagic stroke, and
vascular death. Based on this data, warfarin did no better
than aspirin in stroke prevention but was associated with sig-
niﬁcantly higher rates of adverse events, such that 8.3% of
patients randomized to warfarin had one episode of major
hemorrhage compared to 3.2% of patients randomized to
aspirin therapy [4].
Based on the WASID data, aspirin is the antithrombotic
drug of choice in ICAD. More recent evidence suggests that
dual antiplatelet therapy may be more eﬀective than aspirin
alone in preventing microembolic signals detected with
transcranial Doppler ultrasound with similar adverse events
in both arms [5]. Further evidence is needed to determine if
dual antiplatelet therapy is indeed superior to aspirin alone
in preventing clinical strokes in patients with symptomatic
ICAD.
Although the WASID trial was not designed to study the
importance of risk factor control, several important con-
clusions are reached from its substudies. Thus, while low-
ering blood pressure during followup appears to reduce re-
currence risk [6], the eﬀects of lipid management seem more
controversial [7]. Further studies will be needed to clarify the
role of risk factor management in these patients.
3.2. EC-IC Bypass. Flow augmentation in the setting of an-
terior circulation ischemia can be achieved surgically via
external carotid to internal carotid (EC-IC) bypass pro-
cedures. Typically, the superﬁcial temporal artery (STA) is
anastomosed to the middle cerebral artery (MCA) provided
suﬃcient ﬂow is obtained via the STA (Figure 1). If the STA
demonstrates insuﬃcient ﬂow, the cervical carotid can be
used via an interposition graft, such as the saphenous vein.
The EC-IC study published in 1985 [8] quickly led
to a sharp decline in the use of this intervention for
anterior circulation ICAD, since it failed to demonstrate any
reduction in strokes compared to best medical management.
Brieﬂy, 1377 patients were randomized to surgery plus
medical management versus medical management alone.
Despite bypass patency rates of 96% and a relatively low
complication rate of 3%, long-term followup at 55 months
revealed no beneﬁt with regards to stroke prevention [8].
Upon closer examination, several shortcomings become
apparent in this study. First and foremost, patients who had
ICADwhowerenotamenabletocarotidendarterectomyand
who demonstrated symptoms were included in the study,
with disregard toward hemodynamic compromise. Thus,
patients who may have had disease due to embolic phe-
nomenon and small vessel disease who would not have
beneﬁted from EC-IC were indiscriminately included in the
study. Patients with stage 2 hemodynamic insuﬃciency (i.e.,
those with a higher oxygen extraction fraction (OEF)), have




those who needed the surgery more urgently were omitted,
thus diluting the beneﬁcial eﬀects of the procedure.
In lieu of these criticisms, the Carotid Occlusion Surgery
Study (COSS) [11] and the Japanese EC-IC Bypass Trial
(JET) were underway in the United Stated and Japan, re-
spectively, to assess the potential for a newfound usefulness
of this operation if the patients are selected based on a more
sophisticated analysis of hemodynamic compromise. At the
time of writing this paper, the results of these trials have not
been published; however, COSS was terminated prematurely
due to lack of beneﬁt in patients undergoing EC-IC bypass.
The excimer laser-assisted nonocclusive anastomosis
(ELANA) is a novel bypass technique which critically omits
the use of temporary occlusion using a suction laser catheter
which produces an arteriotomy only after the anastomosis
is created [12]. While the main use of this technique has
been in surgery for complex intracranial aneurysms, recent
work is starting to allude to a potential role for it in ICAD.
In a recent publication, van Doormaal et al. used ELANA
in performing high-ﬂow EC-IC bypasses in 24 patients
with TIA or minor strokes in the setting of carotid artery
occlusion. All patients had a successful bypass procedure.
Twopatientssuﬀeredafatalintracerebralhemorrhagewithin
30 days of the procedure. During an average followup of 4
years, 18 of the surviving 22 patients had patent bypasses
and were free of recurrent symptoms. In the remaining 4,
the bypass had occluded causing ischemic symptoms [13].
Larger, more speciﬁc studies are needed to investigate the
potential use of this novel technique in the treatment of
ICAD.
3.3. Endovascular Therapy. Endovascular devices and exper-
tise using them continue to improve at a rapid pace, and they
representapromisingnewapproachtotreatingsymptomatic
ICAD. Initially, endovascular therapy was limited to percu-
taneous transluminal angioplasty (PTA), but this fell out of
favor due to periprocedural morbidity and mortality along
with signiﬁcant and highly problematic rates of restenosis.
The chief cause of morbidity using PTA alone comes from
vessel dissection, ranging from 14–50% reported in the
literature [14, 15]. In addition, over one quarter (27%)
of treated vessels will demonstrate restenosis at 5 months
following treatment [14, 16]. Ultimately, angioplasty proved
to be only a temporary ﬁx.
The advent of stents, which have the capacity to not
only increase tissue perfusion but also remodel the diseased
vasculature, is an area of increasing promise. Procedural
success rates, periprocedural morbidity and mortality, and
restenosis rates are the chief parameters that are used to
compare diﬀerent stent types in the use of ICAD and are the
subject of much research and controversy.
Drug-eluting stents (DESs) were shown to greatly de-
crease the restenosis rates in coronary artery disease [17],
and there have been attempts to duplicate this success in the








Figure 1: Schematic of STA-MCA bypass.
disease by Abou-Chebl et al. [18]t r e a t i n gas m a l ln u m b e r
of patients demonstrated a similarly promising decrease in
short-term restenosis rates compared to bare metal stents.
However, due to the known risk of delayed stent thrombosis,
combined with the lack of long-term data, DES in the
treatment of ICAD has largely fallen out of practice.
The balloon expandable Pharos stent has showed initial
promise in two small studies in the treatment of ICAD. In
a retrospective study, Freitas et al. treated 32 patients with
>50% stenosis using the Pharos stent with a 96% success
rate. The 30-day clinical followup revealed 2 patients who
had suﬀered ipsilateral stroke and 3 patients who had died,
though 2 of the deaths were likely due to medication non-
compliance. Ten-month clinical followup, however, revealed
no additional strokes ordeaths, and only fourclinically silent
restenosis [19]. A second study from Germany enrolled 21
patients with >70% stenosis, 7 of which were treated in the
setting of acute stroke. They achieved a 90% clinical success
rate. Of the electively treated patients (14), 3 went on to
suﬀer a stroke or die during an average clinical followup
of 7 months. Interestingly, of the 7 patients treated acutely,
2 died within the ﬁrst 30 days, and another 2 went on to
developipsilateralstrokesoverthefollowing10months[20],
reiterating the risk of intracranial stenting in the setting of
acute stroke.
The ﬂexible Wingspan stent was approved for use in
intracranial vessels with >50% stenosis in 2005. The ﬂex-
ibility aﬀorded by this stent increases its usefulness in the
tortuous intracranial vasculature (Figure 2), and technical
success rates using the Wingspan stent have been reported
to be as high as 97-98% [21]. Guo et al. reported a 98%
technical success rate speciﬁcally for MCA stenosis [22],
a vessel traditionally challenging to treat endovascularly.
A prospective Wingspan study, however, demonstrated an
approximately 30% rate of in-stent stenosis [23], higher
than what had previously been reported in the neurosurgical
Figure 2: Stent and balloon catheter commonly used in ICAD.
literature.Whilemostofthesewereclinicallysilent,5%ledto
signiﬁcant morbidity and mortality [23]. In a recent review,
Ding and Liu [24] found the Wingspan stent to have an
overall higher technical success rate in the literature and
possibly a lower complication rate, although the authors
admit that shorter clinical followup for the Wingspan studies
made the comparison uneven.
Due to the initially promising and conﬂicting results of
the Wingspan stent, the SAMMPRIS trial was designed to
compare the Wingspan stent and medical therapy to aggres-
sive medical therapy alone in symptomatic ICAD patients
randomizing patients in 50 centers across the US. At the time
of writing this paper, the results of that trial have not been
published; however, this trial was terminated prematurely
because patients in the angioplasty/stent group fared worse
than those in the medical therapy group. What has been
released about this trial thus far implies that optimizing
medical management remains the ﬁrst treatment of choice
for symptomatic intracranial atherosclerotic disease. The
SAMMPRIS trial did not address those patients who had
failed optimal medical therapy. Endovascular treatment in4 International Journal of Vascular Medicine
these patients may still play an important role in optimizing
clinical outcome.
4. Discussion
ICAD remains a common cause of stroke worldwide, and
our understanding regarding the optimal treatment of it
remainsdismal.TheriskofICAD-associatedstrokeincreases
with high-grade (>70%) stenoses and in those patients who
demonstrate an increased OEF [25]. The conclusion that
these patients need to be treated is likely a sound one,
but the optimal therapy for this group desperately needs
clariﬁcation.
Aspirin,astheantithromboticdrugofchoice,reducesthe
rate of recurrent ipsilateral stroke but does not eliminate
it, and approximately 1 in 7 such patients will go on to
experience recurrent ischemic events [4]. Patients with high-
gradestenosiswhoalsohaveanelevatedOEFwhoexperience
recurrent strokes despite aspirin therapy are in need of
revascularization procedures. The premature termination of
theCOSSstudyimpliesthatmicrosurgicalEC-ICbypassmay
not be the revascularization treatment of choice for these
patients.
Surgery, in the form of EC-IC bypass procedures is yet to
be proven to lower recurrent strokes compared to medical
management only. Previous trials may have been ﬂawed
by indiscriminate inclusion of subjects without the use of
hemodynamic testing to determine who would more likely
b e n e ﬁ tf r o mt h ep r o c e d u r e .T h eC O S Sa n dJ E Tt r i a l sw e r e
initiated to investigate if indeed patients with an elevated
OEF were more likely to beneﬁt from surgery. While the
ﬁnal results of the JET trial are pending, the premature
termination of the COSS trial implies the limited role of EC-
IC bypass in this patient population.
Previous stents were largely designed for coronary dis-
ease, and the tortuous anatomy of the intracranial vascu-
lature limited their utility. The advent of the Wingspan
stent with its ﬂexibility is quite promising, but the initial
results of the SAMMPRIS trial comparing the use of the
Wingspan stent with medical management imply that medi-
cal management remains the treatment of choice for patients
with symptomatic ICAD. The role of angioplasty alone or
angioplasty/stenting in the patient population that has failed
optimal medical management remains to be determined. As
of now, these patients have no other reliable alternative other
than endovascular therapy.
5. Conclusion
Symptomatic ICAD is a signiﬁcant health burden, and often
times, leads to recurrent, disabling strokes. The natural his-
tory of ICAD is poorly understood, as are optimal treatment
strategies.Theresultsoflong-termoutcomestudiesassessing
the utility of both microsurgical and endovascular treatment
options continue to support the fact that optimizing medical
management remains the initial treatment of choice. As
reﬁnements in both microsurgical and endovascular tech-
niques/technologies continue, patients suﬀering from this
devastating disease may have other alternatives.
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